ArticleMolecular pharmaceutics2026
The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In our effort to design an effective ultralow-dose attenuated whole sporozoite (SPZ) vaccine, we explored the use of chemical adjuvants to increase the immunogenicity of sporozoites. Critical to the potency of attenuated sporozoites is their ability to migrate to and infect the liver. We thus used an in vivo mouse challenge model to compare the effects of external and internal chemical modifications to sporozoites. We loaded sporozoites with CL307 using two strategies: a supramolecular surface modification adjuvant system (SPZ-SAS(CL307)) and a mitochondrial membrane potential system (SPZ-MMP(CL307)). SPZ-SAS(CL307) contained 200 times more CL307 as compared to SPZ-MMP(CL307). However, SPZ-SAS(CL307) could not establish a liver infection after intravenous injection (25 000 sporozoites), suggesting loss of function of the sporozoites. On the contrary, SPZ-MMP(CL307) could establish an equivalent liver infection to the control already at a dose of 5000 sporozoites. When the immunized mice were challenged, SPZ-MMP(CL307) equaled the protective efficacy of control sporozoites. Our findings indicate that the MMP system can be used to chemically augment live cells, such as sporozoites, with adjuvants without negatively affecting their infectivity and protective efficacy in vivo. For malaria, further testing of different types of adjuvants at different concentrations is needed to ultimately develop vaccines with increased potency. However, in essence, this platform provides a proof-of-concept for a Trojan horse adjuvanting or drug loading concept for any whole-cell vaccine or therapy, within the infectious diseases space or beyond in oncological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.